Michelle Carr, Author at BioTuesdays

Developments

NRx Pharmaceuticals submits IND for chronic pain

NRx Pharmaceuticals (NASDAQ:NRXP) submitted an investigational new drug (IND) application to the FDA for the use of NRX-101 to treat chronic pain. The IND application leverages pioneering research on the use of D...

August 30, 2023

Developments

Zealand Pharma gets FDA priority review in congenital hyperinsulinism

The FDA granted priority review designation for Zealand Pharma’s (NASDAQ:ZEAL; CVR-no. 20045078) dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients seven days of age and older with...

August 30, 2023

Developments

AEON presents positive Phase results in cervical dystonia

AEON Biopharma (NYSE:AEON) presented positive results from its Phase 2 clinical study of ABP-450 for the treatment of cervical dystonia (CD), a chronic and debilitating neurologic condition affecting the muscles of the...

August 29, 2023

Developments

Anixa Biosciences treats third patient in ovarian cancer CAR-T clinical trial

Anixa Biosciences (NASDAQ:ANIX), in partnership with Moffitt Cancer Center, commenced treatment of the third patient in the ongoing clinical trial of Anixa’s novel chimeric antigen receptor T-cell (CAR-T) therapy...

August 28, 2023

Developments

SK bioscience, Vaxxas in pact for needle-free patch delivery of typhoid vaccine

SK bioscience of South Korea entered into a collaboration agreement with Australia’s Vaxxas to develop a second-generation typhoid conjugate vaccine with support from Wellcome, a global charitable foundation supporting...

August 24, 2023

Developments

Relmada doses first patient in Phase 3 trial for MDD

Relmada Therapeutics (NASDAQ:RLMD) announced dosing the first patient in the Relight Phase 3, randomized, double-blind, placebo-controlled trial evaluating REL-1017 as an adjunctive treatment of major depressive...

August 23, 2023

Developments

Anebulo gets FDA nod for Phase 3 in acute cannabinoid intoxication

The FDA provided positive feedback to Anebulo Pharmaceuticals (NASDAQ:ANEB) for its Phase 3 program of ANEB-001 in patients suffering from acute cannabinoid intoxication (ACI) and substance abuse.

August 21, 2023

Developments

Reviva completes Phase 3 enrollment for brilaroxazine in schizophrenia

Reviva Pharmaceuticals (NASDAQ:RVPH) completed enrollment in the pivotal Phase 3 RECOVER study, evaluating brilaroxazine for schizophrenia, with 402 patients enrolled across 40 sites in the U.S., Europe, and Asia. “We...

August 17, 2023

Developments

Minghui enrolls first patient in Phase 3 trial for atopic dermatitis

Closely-held Minghui Pharmaceutical enrolled the first patient in the Phase 3 clinical study for MH004 cream targeting mild-to-moderate atopic dermatitis, a prevalent skin condition. The randomized, double-blind, and...

August 17, 2023

Developments

Eyenovia acquires U.S. rights for ocular asset from Formosa Pharmaceuticals

Eyenovia (NASDAQ:EYEN) entered an agreement with Taiwan-based Formosa Pharmaceuticals (TWO:6838) to acquire the exclusive U.S. rights to distribute and sell Formosa’s APP13007 (clobetasol propionate ophthalmic...

August 16, 2023

Author - Michelle Carr

NRx Pharmaceuticals submits IND for chronic pain

Zealand Pharma gets FDA priority review in congenital hyperinsulinism

AEON presents positive Phase results in cervical dystonia

Anixa Biosciences treats third patient in ovarian cancer CAR-T clinical trial

SK bioscience, Vaxxas in pact for needle-free patch delivery of typhoid vaccine

Relmada doses first patient in Phase 3 trial for MDD

Anebulo gets FDA nod for Phase 3 in acute cannabinoid intoxication

Reviva completes Phase 3 enrollment for brilaroxazine in schizophrenia

Minghui enrolls first patient in Phase 3 trial for atopic dermatitis

Eyenovia acquires U.S. rights for ocular asset from Formosa Pharmaceuticals

Subscribe